GB0139 is Galecto’s proprietary inhaled once-daily small molecule galectin-3 inhibitor GALACTIC-1 trial on track to deliver top-line results in mid-2023…
Senior Director of Marketing Theresa Ferguson selected as marketing lead for Predictive OncologyEAGAN, Minn., April 26, 2022 (GLOBE NEWSWIRE) --…
DENVER, April 26, 2022 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative…
Conference Call on Tuesday, May 10, 2022 at 8:30 a.m. ETLEXINGTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ:…
FREMONT, CA, April 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical…
PRX012 is a potential best-in-class, subcutaneous anti-amyloid beta antibody therapy currently in a Phase 1 clinical study for the treatment…
BASEL, Switzerland, April 26, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced it will host a webcast and conference…
Physicians To Have Pre-Approval/Expanded Access to Galinpepimut-S (GPS) for Treatment of Patients with Acute Myeloid Leukemia (AML)NEW YORK, April 26,…
MINNEAPOLIS, April 26, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for…
IRVINE, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet…